TcLand Expression S.A.: Clinical Trials

3 trials sponsored by TcLand Expression S.A., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 unknown. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Unknown 1

Follow TcLand Expression S.A.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis
Infliximab, Adalimumab, Etanercept - RheumatoId Arthritis
TerminatedTcLand Expression S.A.2502016-12-012019-12-24
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Rheumatoid Arthritis
TerminatedTcLand Expression S.A.1232011-02-012013-02-01
Assessment Of the Safety and Benefit of Prospective Immunosuppressive Drug Withdrawal in Liver Transplantation and Prediction of Operational Tolerance
Gradual immunosuppression drug withdrawal - Liver Transplantation
Phase 2UnknownHospital Clinic of Barcelona802005-11-012011-04-20

Conditions studied

Arthritis, Rheumatoid (2)

Interventions

Adalimumab (1)  ·  CT-P13 (1)  ·  Certolizumab Pegol (1)  ·  Etanercept (1)  ·  Infliximab (1)  ·  etanercept biosimilar SB4 (1)  ·  golimumab (1)

Countries

France (2)  ·  Spain (2)  ·  Canada (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Lithuania (1)  ·  Netherlands (1)  ·  Romania (1)  ·  Slovakia (1)  ·  Turkey (Türkiye) (1)

Top investigators

Alberto Sanchez-Fueyo, MD (1)  ·  Giuseppe Tisone, MD (1)  ·  Jacques Pirenne, MD (1)